Nordson Corporation Reports Record Fourth Quarter and Fiscal Year 2025 Results
Fourth Quarter:
-
Sales were
$752 million , growth of 1% over prior year -
Earnings per diluted share were
$2.69 -
Adjusted earnings per diluted share were
$3.03 , growth of 9% over prior year
Full Year:
-
Record sales of
$2.8 billion , growth of 4% over prior year’s record sales -
Earnings per diluted share were
$8.51 -
Adjusted earnings per diluted share were
$10.24 , growth of 5% over prior year
Fiscal 2026 Guidance:
-
Fiscal 2026 forecasted sales range between
$2,830 to$2,950 million and adjusted earnings in the range of$10.80 to$11.50
Net income was
EBITDA in the fourth quarter was
Commenting on the Company’s fiscal 2025 fourth quarter results, Nordson President and Chief Executive Officer
Fourth Quarter Segment Results
Industrial
Medical and Fluid Solutions sales of
Fiscal 2025 Full Year Results
Sales for the fiscal year ended
Net income was
EBITDA was
Reflecting on fiscal 2025,
Outlook
Following four consecutive years of record-setting performance, we enter fiscal 2026 with approximately
Based on the combination of order entry, backlog, current exchange rates and anticipated end market expectations, we expect to deliver sales in the range of
First quarter fiscal 2026 sales are forecasted in the range of
Commenting on fiscal 2026 guidance,
Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on
Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” “target,” or the negative of these terms or comparable terminology. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to,
|
SEGMENT INFORMATION (Unaudited) (Dollars in thousands) |
|||||||||||||||||||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||||
|
SALES |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Industrial precision solutions |
$ |
361,713 |
|
|
|
|
$ |
367,195 |
|
|
|
|
$ |
1,331,792 |
|
|
|
|
$ |
1,398,912 |
|
|
|
||||
|
Medical and fluid solutions |
|
219,502 |
|
|
|
|
|
200,223 |
|
|
|
|
|
835,385 |
|
|
|
|
|
695,452 |
|
|
|
||||
|
Advanced technology solutions |
|
170,605 |
|
|
|
|
|
177,064 |
|
|
|
|
|
624,510 |
|
|
|
|
|
595,557 |
|
|
|
||||
|
Total sales |
$ |
751,820 |
|
|
|
|
$ |
744,482 |
|
|
|
|
$ |
2,791,687 |
|
|
|
|
$ |
2,689,921 |
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Industrial precision solutions |
$ |
137,420 |
|
|
38 |
% |
|
$ |
136,244 |
|
|
37 |
% |
|
$ |
493,873 |
|
|
37 |
% |
|
$ |
520,769 |
|
|
37 |
% |
|
Medical and fluid solutions |
|
87,661 |
|
|
40 |
% |
|
|
72,264 |
|
|
36 |
% |
|
|
311,684 |
|
|
37 |
% |
|
|
256,553 |
|
|
37 |
% |
|
Advanced technology solutions |
|
42,756 |
|
|
25 |
% |
|
|
47,564 |
|
|
27 |
% |
|
|
146,589 |
|
|
23 |
% |
|
|
129,181 |
|
|
22 |
% |
|
Corporate expenses |
|
(12,086 |
) |
|
|
|
|
(14,976 |
) |
|
|
|
|
(52,628 |
) |
|
|
|
|
(57,335 |
) |
|
|
||||
|
EBITDA (non-GAAP) (1) |
$ |
255,751 |
|
|
34 |
% |
|
$ |
241,096 |
|
|
32 |
% |
|
$ |
899,518 |
|
|
32 |
% |
|
$ |
849,168 |
|
|
32 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
(1) |
Total company EBITDA is a non-GAAP measure. Refer to the reconciliation of non-GAAP measures – net income to EBITDA. |
|
|
Three Months Ended |
Twelve Months Ended |
||||||||||
|
|
|
|
|
|
|
|||||||
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
||||
|
Industrial precision solutions |
$ |
14,015 |
|
$ |
12,783 |
|
$ |
52,492 |
|
|
$ |
51,187 |
|
Medical and fluid solutions |
|
17,396 |
|
|
17,240 |
|
|
71,588 |
|
|
|
58,062 |
|
Advanced technology solutions |
|
4,683 |
|
|
4,593 |
|
|
18,741 |
|
|
|
19,102 |
|
Corporate expenses |
|
1,975 |
|
|
1,913 |
|
|
7,702 |
|
|
|
7,824 |
|
Total |
$ |
38,069 |
|
$ |
36,529 |
|
$ |
150,523 |
|
|
$ |
136,175 |
|
|
|
|
|
|
|
|
|
|
||||
|
CONSOLIDATED STATEMENT OF INCOME (Unaudited) (Dollars in thousands except for per-share amounts) |
||||||||||||
|
|
Three Months Ended |
Twelve Months Ended |
||||||||||
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
||||||||
|
Sales |
$ |
751,820 |
|
$ |
744,482 |
|
$ |
2,791,687 |
|
$ |
2,689,921 |
|
|
Cost of sales |
|
328,353 |
|
|
341,658 |
|
|
1,251,903 |
|
|
1,203,792 |
|
|
Gross profit |
|
423,467 |
|
|
402,824 |
|
|
1,539,784 |
|
|
1,486,129 |
|
|
Gross margin % |
|
56.3 |
% |
|
54.1 |
% |
|
55.2 |
% |
|
55.2 |
% |
|
|
|
|
|
|
||||||||
|
Selling & administrative expenses |
|
208,872 |
|
|
223,932 |
|
|
815,514 |
|
|
812,128 |
|
|
Divestiture and related charges |
|
334 |
|
|
— |
|
|
12,545 |
|
|
— |
|
|
Operating profit |
|
214,261 |
|
|
178,892 |
|
|
711,725 |
|
|
674,001 |
|
|
|
|
|
|
|
||||||||
|
Interest expense - net |
|
(23,770 |
) |
|
(27,282 |
) |
|
(101,105 |
) |
|
(84,011 |
) |
|
Other expense - net |
|
(7,592 |
) |
|
(3,538 |
) |
|
(12,972 |
) |
|
(4,509 |
) |
|
Income before income taxes |
|
182,899 |
|
|
148,072 |
|
|
597,648 |
|
|
585,481 |
|
|
|
|
|
|
|
||||||||
|
Income taxes |
|
31,265 |
|
|
25,904 |
|
|
113,174 |
|
|
118,197 |
|
|
|
|
|
|
|
||||||||
|
Net Income |
$ |
151,634 |
|
$ |
122,168 |
|
$ |
484,474 |
|
$ |
467,284 |
|
|
|
|
|
|
|
||||||||
|
Weighted-average common shares outstanding: |
|
|
|
|
||||||||
|
Basic |
|
56,077 |
|
|
57,188 |
|
|
56,606 |
|
|
57,176 |
|
|
Diluted |
|
56,417 |
|
|
57,603 |
|
|
56,916 |
|
|
57,616 |
|
|
|
|
|
|
|
||||||||
|
Earnings per share: |
|
|
|
|
||||||||
|
Basic earnings |
$ |
2.70 |
|
$ |
2.14 |
|
$ |
8.56 |
|
$ |
8.17 |
|
|
Diluted earnings |
$ |
2.69 |
|
$ |
2.12 |
|
$ |
8.51 |
|
$ |
8.11 |
|
|
CONSOLIDATED BALANCE SHEET (Unaudited) (Dollars in thousands) |
|||||
|
|
|
|
|
||
|
|
|
|
|
||
|
Cash and cash equivalents |
$ |
108,442 |
|
$ |
115,952 |
|
Receivables - net |
|
587,843 |
|
|
594,663 |
|
Inventories - net |
|
444,814 |
|
|
476,935 |
|
Other current assets |
|
101,752 |
|
|
87,482 |
|
Total current assets |
|
1,242,851 |
|
|
1,275,032 |
|
|
|
|
|
||
|
Property, plant & equipment - net |
|
516,914 |
|
|
544,607 |
|
|
|
3,304,685 |
|
|
3,280,819 |
|
Other assets |
|
853,231 |
|
|
900,508 |
|
|
$ |
5,917,681 |
|
$ |
6,000,966 |
|
|
|
|
|
||
|
Notes payable and debt due within one year |
$ |
315,000 |
|
$ |
103,928 |
|
Accounts payable and accrued liabilities |
|
443,260 |
|
|
424,549 |
|
Total current liabilities |
|
758,260 |
|
|
528,477 |
|
|
|
|
|
||
|
Long-term debt |
|
1,681,254 |
|
|
2,101,197 |
|
Other liabilities |
|
434,596 |
|
|
439,100 |
|
Total shareholders' equity |
|
3,043,571 |
|
|
2,932,192 |
|
|
$ |
5,917,681 |
|
$ |
6,000,966 |
|
|
|
|
|
||
|
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) (Dollars in thousands) |
|||||||
|
|
Twelve Months Ended |
||||||
|
|
|
|
|
||||
|
|
|
|
|
||||
|
Cash flows from operating activities: |
|
|
|
||||
|
Net Income |
$ |
484,474 |
|
|
$ |
467,284 |
|
|
Depreciation and amortization |
|
150,523 |
|
|
|
136,175 |
|
|
Divestiture and related charges |
|
12,545 |
|
|
|
— |
|
|
Other non-cash items |
|
14,806 |
|
|
|
5,883 |
|
|
Changes in operating assets and liabilities and other |
|
56,827 |
|
|
|
(53,149 |
) |
|
Net cash provided by operating activities |
|
719,175 |
|
|
|
556,193 |
|
|
|
|
|
|
||||
|
Cash flows from investing activities: |
|
|
|
||||
|
Additions to property, plant and equipment |
|
(58,060 |
) |
|
|
(64,410 |
) |
|
Sale (acquisition) of businesses, net of cash acquired |
|
28,107 |
|
|
|
(789,996 |
) |
|
Other - net |
|
3,263 |
|
|
|
10,008 |
|
|
Net cash used in investing activities |
|
(26,690 |
) |
|
|
(844,398 |
) |
|
|
|
|
|
||||
|
Cash flows from financing activities: |
|
|
|
||||
|
Issuance (repayment) of long-term debt |
|
(224,141 |
) |
|
|
464,353 |
|
|
Repayment of finance lease obligations |
|
(5,868 |
) |
|
|
(6,148 |
) |
|
Dividends paid |
|
(179,069 |
) |
|
|
(161,438 |
) |
|
Issuance of common shares |
|
9,014 |
|
|
|
31,067 |
|
|
Purchase of treasury shares |
|
(306,367 |
) |
|
|
(33,339 |
) |
|
Net cash provided (used) by financing activities |
|
(706,431 |
) |
|
|
294,495 |
|
|
|
|
|
|
||||
|
Effect of exchange rate change on cash: |
|
6,436 |
|
|
|
(6,017 |
) |
|
Net change in cash and cash equivalents |
|
(7,510 |
) |
|
|
273 |
|
|
|
|
|
|
||||
|
Cash and cash equivalents: |
|
|
|
||||
|
Beginning of period |
|
115,952 |
|
|
|
115,679 |
|
|
End of period |
$ |
108,442 |
|
|
$ |
115,952 |
|
|
|
|
|
|||||
|
SALES BY GEOGRAPHIC SEGMENT (Unaudited) (Dollars in thousands) |
|||||||||||||||||
|
|
Three Months Ended |
|
Sales Variance |
||||||||||||||
|
|
|
|
|
|
Organic |
|
Acquisitions /
|
|
Currency |
|
Total |
||||||
|
SALES BY SEGMENT |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Industrial precision solutions |
$ |
361,713 |
|
$ |
367,195 |
|
(3.5 |
)% |
|
— |
% |
|
2.0 |
% |
|
(1.5 |
)% |
|
Medical and fluid solutions |
|
219,502 |
|
|
200,223 |
|
7.4 |
% |
|
1.6 |
% |
|
0.6 |
% |
|
9.6 |
% |
|
Advanced technology solutions |
|
170,605 |
|
|
177,064 |
|
(4.9 |
)% |
|
— |
% |
|
1.3 |
% |
|
(3.6 |
)% |
|
Total sales |
$ |
751,820 |
|
$ |
744,482 |
|
(1.1 |
)% |
|
0.6 |
% |
|
1.5 |
% |
|
1.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
SALES BY GEOGRAPHIC REGION |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
330,962 |
|
|
323,170 |
|
2.0 |
% |
|
— |
% |
|
0.4 |
% |
|
2.4 |
% |
|
|
|
195,343 |
|
|
185,350 |
|
(1.0 |
)% |
|
1.4 |
% |
|
5.0 |
% |
|
5.4 |
% |
|
|
|
225,515 |
|
|
235,962 |
|
(5.3 |
)% |
|
0.6 |
% |
|
0.3 |
% |
|
(4.4 |
)% |
|
Total sales |
$ |
751,820 |
|
$ |
744,482 |
|
(1.1 |
)% |
|
0.6 |
% |
|
1.5 |
% |
|
1.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Twelve Months Ended |
|
Sales Variance |
||||||||||||||
|
|
|
|
|
|
Organic |
|
Acquisitions /
|
|
Currency |
|
Total |
||||||
|
SALES BY SEGMENT |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Industrial precision solutions |
$ |
1,331,792 |
|
$ |
1,398,912 |
|
(5.1 |
)% |
|
— |
% |
|
0.3 |
% |
|
(4.8 |
)% |
|
Medical and fluid solutions |
|
835,385 |
|
|
695,452 |
|
(3.1 |
)% |
|
23.0 |
% |
|
0.2 |
% |
|
20.1 |
% |
|
Advanced technology solutions |
|
624,510 |
|
|
595,557 |
|
4.1 |
% |
|
— |
% |
|
0.8 |
% |
|
4.9 |
% |
|
Total sales |
$ |
2,791,687 |
|
$ |
2,689,921 |
|
(2.5 |
)% |
|
6.0 |
% |
|
0.3 |
% |
|
3.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
SALES BY GEOGRAPHIC REGION |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
1,205,830 |
|
|
1,178,626 |
|
(6.7 |
)% |
|
9.5 |
% |
|
(0.5 |
)% |
|
2.3 |
% |
|
|
|
722,221 |
|
|
726,100 |
|
(6.7 |
)% |
|
4.2 |
% |
|
2.0 |
% |
|
(0.5 |
)% |
|
|
|
863,636 |
|
|
785,195 |
|
7.6 |
% |
|
2.3 |
% |
|
0.1 |
% |
|
10.0 |
% |
|
Total sales |
$ |
2,791,687 |
|
$ |
2,689,921 |
|
(2.5 |
)% |
|
6.0 |
% |
|
0.3 |
% |
|
3.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
RECONCILIATION OF NON-GAAP MEASURES - NET INCOME to EBITDA (Unaudited) (Dollars in thousands) |
|||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||
|
|
|
|
|
|
|
|
|
||||
|
Net income |
$ |
151,634 |
|
$ |
122,168 |
|
$ |
484,474 |
|
$ |
467,284 |
|
Income taxes |
|
31,265 |
|
|
25,904 |
|
|
113,174 |
|
|
118,197 |
|
Interest expense - net |
|
23,770 |
|
|
27,282 |
|
|
101,105 |
|
|
84,011 |
|
Other (income) expense - net |
|
7,592 |
|
|
3,538 |
|
|
12,972 |
|
|
4,509 |
|
Inventory step-up amortization (1) |
|
— |
|
|
4,759 |
|
|
3,135 |
|
|
7,703 |
|
Severance and other (1) |
|
2,531 |
|
|
12,717 |
|
|
19,256 |
|
|
17,332 |
|
Acquisition-related costs (1) |
|
556 |
|
|
8,200 |
|
|
2,334 |
|
|
13,957 |
|
Divestiture and related charges (2) |
|
334 |
|
|
— |
|
|
12,545 |
|
|
— |
|
Adjusted operating profit |
|
217,682 |
|
|
204,568 |
|
|
748,995 |
|
|
712,993 |
|
Depreciation and amortization |
|
38,069 |
|
|
36,528 |
|
|
150,523 |
|
|
136,175 |
|
EBITDA (non-GAAP) (3) |
$ |
255,751 |
|
$ |
241,096 |
|
$ |
899,518 |
|
$ |
849,168 |
|
(1) |
Represents non-recurring cost reduction actions as well as fees and non-cash inventory charges associated with acquisitions. |
|
(2) |
Represents the loss on sale and other charges associated with the exit of the medical contract manufacturing business. |
|
(3) |
EBITDA is a non-GAAP measure used by management to evaluate the Company's ongoing operations. EBITDA is defined as operating profit plus certain adjustments, such as non-recurring cost reduction actions, fees and non-cash inventory charges associated with acquisitions, plus depreciation and amortization. |
|
RECONCILIATION OF NON-GAAP MEASURES - ADJUSTED NET INCOME AND EARNINGS PER SHARE (Unaudited) (Dollars in thousands) |
|||||||||||
|
|
Three Months Ended |
|
Twelve Months Ended |
||||||||
|
|
|
|
|
|
|
|
|
||||
|
GAAP AS REPORTED |
|
|
|
|
|
|
|
||||
|
Net income |
$ |
151,634 |
|
$ |
122,168 |
|
$ |
484,474 |
|
$ |
467,284 |
|
Diluted earnings per share |
$ |
2.69 |
|
$ |
2.12 |
|
$ |
8.51 |
|
$ |
8.11 |
|
|
|
|
|
|
|
|
|
||||
|
Shares outstanding - diluted |
|
56,417 |
|
|
57,603 |
|
|
56,916 |
|
|
57,616 |
|
|
|
|
|
|
|
|
|
||||
|
ADJUSTMENTS |
|
|
|
|
|
|
|
||||
|
Inventory step-up amortization (1) |
$ |
— |
|
$ |
4,759 |
|
$ |
3,135 |
|
$ |
7,703 |
|
Acquisition costs (1) |
|
556 |
|
|
8,200 |
|
|
2,334 |
|
|
13,957 |
|
Severance and other (1) |
|
2,531 |
|
|
12,717 |
|
|
19,256 |
|
|
17,332 |
|
Divestiture and related charges (2) |
|
334 |
|
|
— |
|
|
12,545 |
|
|
— |
|
Acquisition amortization of intangibles |
|
20,165 |
|
|
19,560 |
|
|
79,264 |
|
|
76,972 |
|
Entity liquidation |
|
— |
|
|
— |
|
|
988 |
|
|
— |
|
Interest |
|
— |
|
|
908 |
|
|
— |
|
|
908 |
|
Total adjustments |
$ |
23,586 |
|
$ |
46,144 |
|
$ |
117,522 |
|
$ |
116,872 |
|
|
|
|
|
|
|
|
|
||||
|
Adjustments net of tax |
$ |
19,554 |
|
$ |
38,071 |
|
$ |
98,259 |
|
$ |
93,278 |
|
EPS effect of adjustments |
$ |
0.35 |
|
$ |
0.66 |
|
$ |
1.73 |
|
$ |
1.62 |
|
|
|
|
|
|
|
|
|
||||
|
NON-GAAP |
|||||||||||
|
Adjusted net income (3) |
$ |
171,188 |
|
$ |
160,239 |
|
$ |
582,733 |
|
$ |
560,562 |
|
Adjusted earnings per share (4) |
$ |
3.03 |
|
$ |
2.78 |
|
$ |
10.24 |
|
$ |
9.73 |
|
(1) |
Represents non-recurring cost reduction actions as well as fees and non-cash inventory charges associated with acquisitions. |
|
(2) |
Represents the loss on sale and other charges associated with the exit of the medical contract manufacturing business. |
|
(3) |
Adjusted net income is a non-GAAP measure defined as net income plus tax effected adjustments and other discrete tax items. |
|
(4) |
Adjusted earnings per share is a non-GAAP measure defined as GAAP EPS adjusted for tax effected adjustments and other discrete tax items. |
|
RECONCILIATION OF NON-GAAP MEASURES - OPERATING CASH FLOW TO FREE CASH FLOW (Unaudited) (Dollars in thousands) |
||||||
|
|
Year to Date |
|||||
|
|
|
|
||||
|
Net cash provided by operating activities |
$ |
719,175 |
|
$ |
516,264 |
|
|
Additions to property, plant and equipment |
|
(58,060 |
) |
|
(49,002 |
) |
|
Free Cash Flow - Year to Date (1) |
$ |
661,115 |
|
$ |
467,262 |
|
|
|
|
|
||||
|
Free Cash Flow - Quarter to Date (1) |
$ |
193,853 |
|
|
||
|
|
|
|
||||
|
Net Income - Year to Date |
$ |
484,474 |
|
$ |
332,840 |
|
|
Free Cash Flow Conversion - Year to Date (2) |
|
136 |
% |
|
140 |
% |
|
|
|
|
||||
|
Net Income - Quarter to Date |
$ |
151,634 |
|
|
||
|
Free Cash Flow Conversion - Quarter to Date (2) |
|
128 |
% |
|
||
|
|
|
|
||||
|
|
Year to Date |
|||||
|
|
|
|
||||
|
Net cash provided by operating activities |
$ |
556,193 |
|
$ |
459,812 |
|
|
Additions to property, plant and equipment |
|
(64,410 |
) |
|
(43,786 |
) |
|
Free Cash Flow - Year to Date (1) |
$ |
491,783 |
|
$ |
416,026 |
|
|
|
|
|
||||
|
Free Cash Flow - Quarter to Date (1) |
$ |
75,757 |
|
|
||
|
(1) |
Free Cash Flow is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Net cash provided by operating activities minus Additions to property, plant and equipment. |
|
(2) |
Free Cash Flow Conversion is a non-GAAP measure used by management to evaluate the Company's ongoing operations and is defined as Free Cash Flow divided by Net Income. |
Management uses certain non-GAAP measures, such as adjusted net income, adjusted EPS and EBITDA, internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251210630295/en/
Vice President
Investor Relations & Corporate Communications
440.204.9985
Lara.Mahoney@nordson.com
Source: